3D Ultrasound Market Size, Share, Growth Analysis, By Application(General Imaging, Cardiovascular, Obstetrics and gynecology, Point of care), By End-use(Handheld and cart), By Region - Industry Forecast 2024-2031

Global 3D Ultrasound Market size was valued at USD 3.9 billion in 2019 and is poised to grow from USD 4.31 billion in 2023 to USD 9.6 billion by 2031, growing at a CAGR of 10.53% in the forecast period (2024-2031).

The 3d Ultrasound Market competitive landscape provides details by competitor. The global 3D ultrasound market is fragmented, with a few large and medium-sized players accounting for majority of market revenue. Established companies are engaged in various research and development activities and initiatives to develop and deploy new and more efficient technologies in the 3D ultrasound market. 'General Electric Company', 'Koninklijke Philips N.V.', 'Siemens AG', 'Toshiba Corporation', 'Fujifilm Holdings Corporation', 'Hitachi Ltd.', 'Esaote SpA', 'Samsung Medison Co., Ltd.', 'Mindray Medical International Limited', 'Analogic Corporation', 'Terason Ultrasound', 'Shenzhen Mindray Bio-Medical Electronics Co., Ltd.', 'Alpinion Medical Systems Co., Ltd.', 'ContextVision AB', 'Mobisante, Inc.', 'EchoNous, Inc.', 'Clarius Mobile Health', 'Butterfly Network, Inc.', 'SonoScape Medical Corporation', 'Analogic Corporation'

As ultrasound technologies are cost-effective, safer, and offer earlier diagnosis & treatment of target diseases, their demand in disease management is expected to increase during the forecast period. The adoption of effective diagnostic and therapeutic procedure boost due to high and increasing incidence of target diseases and condition. Intrauterine contraceptive devices are extensively being utilized across the world owing to their effectiveness in preventing pregnancy.

Due to higher precision and sensitivity, the general imaging segment is expected to account for the largest revenue share over the forecast period. Since real-time 3D ultrasound offers interactive feedback to assist doctors in obtaining high-quality images, as well as timely spatial information of scanned area, it is essential for intraoperative ultrasound examinations and has drawn a lot of interest in medical research. The cart-based devices segment accounted for the largest revenue share in 2021. Point-of-Care Ultrasound (POCUS) scanners that are cart-based have started to gain popularity. These scanners were developed with POCUS users in mind, fusing best attributes of portable and conventional devices. Over the forecast period, the hospitals segment is expected to account for the largest revenue share. Government spending on modernization of healthcare facilities is rising and rapidly developing technology has led to the creation of compact, sophisticated 3D ultrasound devices, which are being quickly adopted in hospitals and diagnostic institutions. It drives the growth of the market. Recent technological trends in ultrasound are leading to contrast-enhanced imaging and with the advent of mobile technologies, the ultrasound will not remain confined inside hospital premises. Further, with the increase in computational power, ultrasound fusion imaging techniques are gaining significant traction, which will effectively explore the anatomical body parts and organs with the help of real-time ultrasound images. Moreover, with increasing prevalence of heart diseases, gynaecological disorders, and rising awareness on harmful effects of radiation dose is driving the interest of manufacturers towards the development of more advanced ultrasound devices.

North America accounted for the largest market share and is expected to maintain its dominance over the forecast period. North America dominance is contributed by factors such as increasing number of product launches and favourable reimbursement. In the field of 3D imaging, the region is also witnessing continuous technological advancement. Moreover, increasing research and development expenses and a rising patient pool are also boosting the market growth. According to the Centers for Disease Control and Prevention (CDC), osteoarthritis affects over 30 million persons in the U.S. Ultrasound-guided injections play an essential role in treating osteoarthritis and are more effective than oral medicines. USFDA's Center for Devices and Radiological Health (CDRH), is working towards reducing unnecessary radiation exposure from medical imaging. It has started an initiative in response to safety concerns raised in FDA's Safety Investigation of CT Brain Perfusion Scans and rising exposure to ionizing radiation from medical imaging that was highlighted in National Council on Radiation Protection and Measurements. Furthermore, demand for 3D ultrasound is expected to increase due to its non-ionizing radiation and non-invasive procedure, which is expected to drive market revenue growth in this region.